Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Frequently asked questions
What sector does Zentalis Pharmaceuticals Llc (ZNTL) operate in?
Zentalis Pharmaceuticals Llc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Zentalis Pharmaceuticals Llc (ZNTL) current stock price?
As of the latest data, Zentalis Pharmaceuticals Llc stock price is $2.07, with a previous close of $2.21. Zentalis Pharmaceuticals Llc lost -$0.14 in the last trading session, representing a -6.33% loss.
What is Zentalis Pharmaceuticals Llc (ZNTL) current market capitalization?
Zentalis Pharmaceuticals Llc market cap is approximately 203.11 million.
What is Zentalis Pharmaceuticals Llc (ZNTL) Earnings Per Share (EPS)?
The trailing EPS is -$1.96, and the forward EPS is -$1.82.
What is Zentalis Pharmaceuticals Llc (ZNTL) EBITDA?
Zentalis Pharmaceuticals Llc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -77.23 million.
Does Zentalis Pharmaceuticals Llc (ZNTL) pay dividends?
No. Zentalis Pharmaceuticals Llc does not pay a dividend.
When is Zentalis Pharmaceuticals Llc (ZNTL) next earnings report?
Zentalis Pharmaceuticals Llc is expected to release its next earnings report on September 30, 2026.
What is Zentalis Pharmaceuticals Llc (ZNTL) beta (volatility) score?
Zentalis Pharmaceuticals Llc has a beta of 1.938, suggesting it is more volatile than the market.
